转移性肾细胞癌患者中白细胞介素2临床反应与HLA表型之间的相关性
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
作者信息
Bain C, Merrouche Y, Puisieux I, Blay J Y, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot M C
机构信息
Department of Tumor Biology, Centre Léon Bérard, Lyon, France.
出版信息
Br J Cancer. 1997;75(2):283-6. doi: 10.1038/bjc.1997.46.
Abstract
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.
摘要
对79例接受白细胞介素2（IL-2）治疗的转移性肾细胞癌患者的HLA表型进行了特征分析。HLA - A32与临床反应相关（P = 0.025）。有反应者中HLA - A3和/或A32的频率高于无反应者（P = 0.008）。因此，这些结果表明，在体内，IL - 2可能增强针对肿瘤抗原的细胞介导免疫，并且某些MHC分子在内源性肿瘤抗原呈递方面比其他分子更有效。
相似文献
1
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.转移性肾细胞癌患者中白细胞介素2临床反应与HLA表型之间的相关性
Br J Cancer. 1997;75(2):283-6. doi: 10.1038/bjc.1997.46.
2
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.晚期肾细胞癌中的HLA表型与细胞因子诱导的肿瘤控制
Cancer Biother Radiopharm. 2001 Oct;16(5):401-9. doi: 10.1089/108497801753354302.
3
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.转移性肾细胞癌患者经白细胞介素-2 为基础的免疫治疗潜在治愈者中碳酸酐酶 IX 特异性免疫反应。
Immunopharmacol Immunotoxicol. 2013 Aug;35(4):487-96. doi: 10.3109/08923973.2013.802802. Epub 2013 Jun 27.
4
Low-dose regimen of interleukin-2 for metastatic renal carcinoma.低剂量白细胞介素-2治疗转移性肾癌方案
Lancet. 1990 Jun 23;335(8704):1522-3. doi: 10.1016/0140-6736(90)93057-v.
5
Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.接受白细胞介素-2治疗的转移性肾细胞癌患者生存的预后标志物。
Cancer Immunol Immunother. 1996 Dec;43(5):293-8. doi: 10.1007/s002620050336.
6
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.肾细胞癌患者皮下注射重组白细胞介素-2治疗期间早期可溶性CD8血浆水平与疗效相关。
Br J Cancer. 1993 May;67(5):1118-21. doi: 10.1038/bjc.1993.205.
7
Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.白细胞介素-2预处理可调节肾细胞癌患者围手术期的免疫功能障碍。
Eur Urol. 2002 Apr;41(4):458-67; discussion 467-8. doi: 10.1016/s0302-2838(02)00031-3.
8
HLA class I expression in primary and metastatic renal cell carcinoma.原发性和转移性肾细胞癌中HLA I类分子的表达
Investig Urol (Berl). 1994;5:55-9.
9
Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.白细胞介素-2预处理可调节肾细胞癌患者围手术期的免疫功能障碍。
Folia Biol (Praha). 2003;49(2):63-8.
10
Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy.肾细胞癌病变中人类白细胞抗原的表达不能预测对干扰素治疗的反应。
J Immunother (1991). 1992 Jul;12(1):64-9. doi: 10.1097/00002371-199207000-00008.
引用本文的文献
1
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.一项针对接受 AE37Ii-key-HER-2/neu 多肽疫苗治疗的前列腺癌患者的初步研究表明，HLA-A*24 和 HLA-DRB1*11 等位基因可能是临床获益的预后和预测生物标志物。
Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31.
2
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.HLA-A02* 基因型与 HLA Ⅰ类抗原下调与上皮性卵巢癌预后的相关性。
Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19.
3
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.常见的斯堪的纳维亚人白细胞抗原祖传单倍型62.1作为晚期恶性黑色素瘤患者的预后因素。
Cancer Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 10.1007/s00262-009-0669-8. Epub 2009 Feb 13.
4
Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?肾细胞癌中的细胞因子反应是治疗的安慰剂效应的产物还是真正的生物疗法？现在需要哪些试验？
Br J Cancer. 1998 Apr;77(8):1318-20. doi: 10.1038/bjc.1998.219.
本文引用的文献
1
GENETIC BASIS OF SUSCEPTIBILITY TO VIRAL LEUKAEMOGENESIS.病毒致白血病易感性的遗传基础。
Lancet. 1964 Dec 5;2(7371):1207-9. doi: 10.1016/s0140-6736(64)91043-8.
2
B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells.人肾癌细胞系的B7.1基因转导可恢复同种异体T细胞的增殖反应和细胞毒性功能。
Int J Cancer. 1996 Sep 17;67(6):769-76. doi: 10.1002/(SICI)1097-0215(19960917)67:6<769::AID-IJC4>3.0.CO;2-P.
3
HLA associations in the antitumor response against malignant melanoma.HLA在抗恶性黑色素瘤抗肿瘤反应中的关联。
J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):242-52. doi: 10.1097/00002371-199511000-00005.
4
5
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.浸润人肾细胞癌的T细胞中T细胞受体ζ链和p56lck缺失。
Cancer Res. 1993 Dec 1;53(23):5613-6.
6
Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.针对人肾细胞癌的细胞免疫反应：由HLA - A2限制的细胞毒性T淋巴细胞（CTL）克隆识别的共同抗原的定义。
Int J Cancer. 1994 Dec 15;59(6):837-42. doi: 10.1002/ijc.2910590621.
7
HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2).人类白细胞抗原I类等位基因与黑色素瘤对α干扰素（IFN-α）和白细胞介素-2（IL-2）免疫治疗的反应性。
Melanoma Res. 1994 Jun;4(3):191-4. doi: 10.1097/00008390-199406000-00008.
8
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.逆转录病毒基因转移在肿瘤学中的临床应用：一项法国研究的结果，该研究用对新霉素耐药的基因转导肿瘤浸润淋巴细胞。
J Clin Oncol. 1995 Feb;13(2):410-8. doi: 10.1200/JCO.1995.13.2.410.
9
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes.肾细胞癌肿瘤细胞和肿瘤浸润淋巴细胞中细胞因子基因的选择性表达。
Int J Cancer. 1995 Jun 9;61(6):780-5. doi: 10.1002/ijc.2910610607.
Zotero 插件